Workflow
8月4日中银创新医疗混合C净值下跌0.72%,近1个月累计上涨10.05%

Group 1 - The core point of the news is the performance of the Zhongyin Innovation Medical Mixed C Fund, which has shown significant returns over various time frames, with a year-to-date return of 80.47% and a recent one-month return of 10.05% [1] - As of June 30, 2025, the fund's total assets amounted to 2.686 billion yuan, indicating a substantial scale for a fund established in October 2020 [1] - The top ten stock holdings of the fund account for a combined 62.83%, with notable investments in companies such as Innovent Biologics (8.33%) and Hengrui Medicine (8.08%) [1] Group 2 - The fund manager, Zheng Ning, has a strong background in the investment industry, having previously held senior positions at Taikang Asset Management and Zhonggeng Fund Management [2] - Zheng Ning has been managing the Zhongyin Innovation Medical Mixed Fund since July 1, 2022, and has also taken on managerial roles for other funds within the Zhongyin family [2]